TEMPLE CITY, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Fulgent Genetics announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $9.00 per share, before underwriting discounts and commissions. Fulgent Genetics has granted the underwriters a 30-day option to purchase up to an additional 630,000 shares from the company at the same price. The shares are expected to begin trading on The NASDAQ Global Market on September 29, 2016, under the ticker symbol “FLGT.” The offering is expected to close on October 4, 2016, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC and Piper Jaffray & Co. are serving as joint book-running managers for the offering. Raymond James & Associates, Inc. is serving as lead manager and BTIG, LLC is serving as co-manager.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on September 28, 2016. The offering is being made solely by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, by telephone at +1-800-221-1037, or by email at firstname.lastname@example.org; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Suite 800, Minneapolis, MN 55402, by telephone at +1-800-747-3924, or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Last updated on: 29/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.